Annji Pharmaceutical Co (ROCO:7754) Retained Earnings: NT$-1,865.16 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7754 Annji Pharmaceutical Co Ltd ROCO:7754
11 GF Score
Price NT$54.10
! 3 Warning Signs
View Full Analysis

What is Annji Pharmaceutical Co Retained Earnings?

Annji Pharmaceutical Co ROCO:7754 -1.10% 11 Retained Earnings is NT$-1,865.16 Mil as of Jun. 2026. GuruFocus rates ROCO:7754 with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Annji Pharmaceutical Co's retained earnings for the quarter that ended in Jun. 2026 was NT$-1,865.16 Mil.

Annji Pharmaceutical Co's quarterly retained earnings declined from Jun. 2025 (NT$-1,459.20 Mil) to Dec. 2025 (NT$-1,657.87 Mil) and declined from Dec. 2025 (NT$-1,657.87 Mil) to Jun. 2026 (NT$-1,865.16 Mil).

Annji Pharmaceutical Co's annual retained earnings declined from Dec. 2023 (NT$-946.02 Mil) to Dec. 2024 (NT$-1,300.00 Mil) and declined from Dec. 2024 (NT$-1,300.00 Mil) to Dec. 2025 (NT$-1,657.87 Mil).


Annji Pharmaceutical Co  (ROCO:7754) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Annji Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Annji Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co Retained Earnings Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
-380.15 -616.80 -946.02 -1,300.00 -1,657.87

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only -1,142.07 -1,300.00 -1,459.20 -1,657.87 -1,865.16
ROCO:7754
11GF Score
Annji Pharmaceutical Co Ltd ROCO:7754
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annji Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of NT$-1,865.16 Mil mean?
Annji Pharmaceutical Co (ROCO:7754) has a Retained Earnings of NT$-1,865.16 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Annji Pharmaceutical Co and its competitors.
Is Annji Pharmaceutical Co's Retained Earnings too high?
Annji Pharmaceutical Co's current Retained Earnings is NT$-1,865.16 Mil. Overall, Annji Pharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's Retained Earnings compare to VRTX and REGN?
Annji Pharmaceutical Co's Retained Earnings of NT$-1,865.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current Retained Earnings is NT$-1,865.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current Retained Earnings of NT$-1,865.16 Mil. The current Retained Earnings is NT$-1,865.16 Mil. Annji Pharmaceutical Co's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current Retained Earnings is NT$-1,865.16 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annji Pharmaceutical Co Business Description

Address Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
11GF Score

Get the complete analysis for ROCO:7754

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$54.10
Price